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Abstract 
Anogenital warts are an infectious disorder of the anogenital lesion caused by one or 
more human papilloma viruses. Verruca is commonly treated with freezing with liquid 
nitrogen, laser therapy or application of imiquimod. Such ablative treatment may cause 
pain and scars on the anogenital lesion. We herein report an infant case of anogenital 
wart which was successfully treated with a topical vitamin D3 derivative. Topical 
application of a vitamin D3 derivative may be an alternative therapy for anogenital warts 
in infants. 
Introduction 
Anogenital warts are an infectious, proliferating disorder of the anogenital lesion 
caused by one or more human papilloma viruses (HPVs). In the United States, anogenital 
warts are treated with patient-applied chemical treatment of imiquimod and podofilox, 
physician-applied chemical treatment of podophyllin resin and trichloroacetic acid, and 
ablative treatment of cryotherapy with liquid nitrogen and laser therapy [1]. Recently, 
treatment with topical vitamin D3 derivatives has been reported to be effective for HPV-
infected verruca [2–6]. Here, we report an infant case with an anogenital wart on the 
anus, which was successfully treated with calcipotriene ointment, a vitamin D3 derivative. 
Case Report 
A 1-year- and 1-month-old male presented with an anogenital wart on the anus without suspicious 
episodes of infection (fig. 1). The parents had no experience with anogenital warts. The wart did not  
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invade into the rectum and colon. After obtaining informed consent from the parents, we treated the 
wart with a topical vitamin D3 derivative of calcipotriene ointment with simple application to the 
affected lesion twice a day. An initial response of partial regression was observed 2 months later. The 
apparent regression was achieved 3 months later. Complete regression was confirmed 4 months later 
(fig. 2). The anogenital wart did not recur for 6 months after complete regression. 
Discussion 
Anogenital warts are uncommon in children. Skin biopsy and identifying the type of 
HPV are required to diagnose precisely. Unfortunately, we could not take biopsies from 
the affected lesion. Therefore, our diagnosis was only based on the clinical appearance. 
Anogenital warts in children have been reported to be associated with both mucosotropic 
(HPV6 and 11) and cutaneotropic types (HPV2) of the virus [7]. Recent investigation of 
HPV typing in nonabused preschool children showed that 3 (1.8%) of 211 children had 
clinically detectable anogenital warts and that 7 samples from 5 children were HPV-
positive (HPV6 and/or 16), detected by polymerase chain reaction [8]. As our patient had 
anogenital wart only on the mucocutaneous lesion, we surmise that our case was a 
nonabuse case of anogenital wart caused by mucosotropic HPV. 
Verruca is usually treated with freezing with liquid nitrogen, laser therapy or 
application of imiquimod. Such ablative treatment may cause pain and scars. Especially, 
scarring may entail dysfunction of the anus and genital lesion. Topical imiquimod and 
podofilox were not available in Japan at that time. We medicated the patient with a 
therapy for the anogenital wart with a topical vitamin D3 derivative. Our case was 
successfully treated with simple application of calcipotriene ointment to the lesion. Using 
diapers for the infant patient may bring the occlusive condition. 
Previously, the effect of vitamin D3 derivatives on verruca was speculated to be derived 
from its potential to regulate epidermal cell proliferation and differentiation and to 
modulate cytokine production [2, 3]. An important observation was reported which 
suggested that toll-like receptor (TLR) activation of human macrophages upregulated 
expression of vitamin D receptor and vitamin D-1-hydroxylase genes, leading to 
induction of the antimicrobial peptide [9]. This suggests an association of TLRs and 
vitamin D-mediated innate immunity [9]. Treatment with imiquimod for anogenital 
warts in an infant was shown to be highly effective [10]. Imiquimod induces the secretion 
of proinflammatory cytokines and the reaction of antitumor and antiviral cellular innate 
immunity through TLR 7- and 8-signaling cascade. We surmised that imiquimod and 
vitamin D3 derivatives, to some extent, share the same antiviral efficacy. 
Previously, Egawa reported the effectiveness of a topical vitamin D3 derivative for 
condylomata acuminata on the corona and glans in a 74-year-old man with simple 
application twice a day for 4 months [6]. The infected duration of anogenital warts in 
adults varies from a few weeks to many years [11]. It took 4 months for the treatment of 
the anogenital wart in our infant patient. The possibility of a potent placebo effect was not 
excluded. A prospective placebo-controlled study is required to evaluate the actual 
efficacy. 
We reported an infant having anogenital wart successfully treated with a vitamin D3 
derivative without developing pain, scar or dysfunction. We propose that topical 
application of a vitamin D3 derivative may be an alternative therapy for anogenital warts 
in infants. 
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Fig. 1. Anogenital wart on the anus before treatment. 
 
 
 
Fig. 2. Complete healing of the anogenital wart 4 months after starting treatment with topical 
application of a vitamin D3 derivative. 
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